John Ødegård
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
John Ødegård has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Dagny Lise Sandnes
Department of Pharmacology, Institute of Clinical Medicine, University of Oslo, Oslo, Norway
2 shared publications - Ingun Heiene Tveteraas
Department of Pharmacology, Institute of Clinical Medicine, Faculty of Medicine, University of Oslo and Oslo University Hospital, P.O. Box 1057, Blindern, N-0316, Oslo, Norway.
2 shared publications - Kristin Meisdalen Müller
Department of Pharmacology, Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, P.O.Box 1057 Blindern, N-0316 Oslo, Norway
2 shared publications - Monica Aasrum
Department of Pharmacology, Faculty of Medicine, University of Oslo and Oslo University Hospital, Oslo, Norway
2 shared publications - Thoralf Christoffersen
Department of Pharmacology, Faculty of Medicine, University of Oslo, Oslo, Norway
2 shared publications - Mona Dawood
Department of Pharmacology, Institute of Clinical Medicine, Faculty of Medicine and Oslo University Hospital, University of Oslo, Oslo, Norway
1 shared publication
Latest Publications
- Open Access
- 11 September 2012
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
- Vol. 31 (1) , 72
Mechanisms involved in PGE2-induced transactivation of the epidermal growth factor receptor in MH1C1 hepatocarcinoma cells
It is important to understand the mechanisms by which the cells integrate signals from different receptors. Several lines of evidence implicate epidermal growth factor (EGF) receptor (EGFR) in the pathophysiology of hepatocarcinomas. Data also suggest a role of prostaglandins in some of these tumours, through their receptors of the G protein-coupled receptor (GPCR) family. In this study we have investigated mechanisms of interaction between signalling from prostaglandin receptors and EGFR in hepatocarcinoma cells.
- 11 September 2012
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
- Vol. 31 (1) , 72
Open AccessMechanisms involved in PGE2-induced transactivation of the epidermal growth factor receptor in MH1C1 hepatocarcinoma cells
It is important to understand the mechanisms by which the cells integrate signals from different receptors. Several lines of evidence implicate epidermal growth factor (EGF) receptor (EGFR) in the pathophysiology of hepatocarcinomas. Data also suggest a role of prostaglandins in some of these tumours, through their receptors of the G protein-coupled receptor (GPCR) family. In this study we have investigated mechanisms of interaction between signalling from prostaglandin receptors and EGFR in hepatocarcinoma cells.
- Open Access
- 2 October 2011
- Published by Springer Nature in BMC Cancer
- Vol. 11 (1) , 421
Role of protein kinase C and epidermal growth factor receptor signalling in growth stimulation by neurotensin in colon carcinoma cells
Neurotensin has been found to promote colon carcinogenesis in rats and mice, and proliferation of human colon carcinoma cell lines, but the mechanisms involved are not clear. We have examined signalling pathways activated by neurotensin in colorectal and pancreatic carcinoma cells.
- 2 October 2011
- Published by Springer Nature in BMC Cancer
- Vol. 11 (1) , 421
Open AccessRole of protein kinase C and epidermal growth factor receptor signalling in growth stimulation by neurotensin in colon carcinoma cells
Neurotensin has been found to promote colon carcinogenesis in rats and mice, and proliferation of human colon carcinoma cell lines, but the mechanisms involved are not clear. We have examined signalling pathways activated by neurotensin in colorectal and pancreatic carcinoma cells.